NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1929.10 -55.50 (-2.80%)

1.1M NSE+BSE Volume

NSE 31 Jul, 2025 3:31 PM (IST)

88,111.1

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Lupin Ltd. is on 05 Aug 2025 for the purpose of Quarterly Results & Others See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

09 Nov 2024

1929.10

-2.80%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

08 Aug 2024

1929.10

-2.80%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the Stock

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

07 Aug 2024

1929.10

-2.80%

Strong Q1; complex products to drive growth

Buy: Lupin Ltd.

Target

Sharekhan

Q1FY2025 numbers were strong, beating our estimates on all fronts. Sales grew by 16% y-o-y to Rs. 5514 crore (9% above our estimates), on a 28% y-o-y growth in North America region to Rs. 2041 crore.

Lupin Ltd. has an average target of 2429.71 from 7 brokers.

Lupin Ltd.

07 Aug 2024

1929.10

-2.80%

Strong beat; US/India drive earnings

Neutral: Lupin Ltd.

Target

Motilal Oswal

LPC delivered a strong earnings beat in 1QFY25, led by a superior show in key markets (US/India), lower R&D spending and a low tax rate.

Lupin Ltd.'s price crossed below 30Day SMA today

Lupin Ltd.

10 Jul 2024

1929.10

-2.80%

Launches critical for sustenance of turnaround

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio. Share of inhalation products has risen from 25% of US sales in FY22 (USD 185mn) to 40% in FY24
(USD 326mn) post the launch of gSpiriva. In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15% in FY23 to 11% in Q4FY24).

Lupin Ltd. has an average target of 2429.71 from 7 brokers.

Lupin Ltd.

15 May 2024

1929.10

-2.80%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

08 May 2024

1929.10

-2.80%

Niche product drives earnings growth

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended
FY24 on a strong note, with INR198b in sales (up 19% YoY), EBITDA margin of
18% (up 750bp YoY) and PAT of INR19b (vs. INR4b YoY). LPC continues to
implement efforts toward building a complex product pipeline in inhalation,
injectables and ophthalmics.

Lupin Ltd.'s price crossed below 30Day SMA today

Lupin Ltd.

08 May 2024

1929.10

-2.80%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the stock

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

08 May 2024

1929.10

-2.80%

Lupin (HOLD): Stable margins; higher tax weighs on PAT

Hold: Lupin Ltd.

Target

BOB Capital Markets Ltd.

LPC delivered a healthy operational performance in Q4 with largely in-line revenue/PAT; higher tax impacted net profit

Lupin Ltd.'s price crossed below 30Day SMA today

Lupin Ltd.

07 May 2024

1929.10

-2.80%

Mixed Earnings; healthy pipeline of complex products to drive growth

Buy: Lupin Ltd.

Sharekhan

Lupin reported a mix set of earnings where sales were 4% below our estimates at Rs. 4,895 crore. EBITDA was 4% below our estimates at Rs. 997 crore, while adjusted PAT was in-line with our estimate of Rs. 561 crore.

Lupin Ltd. is trading below all available SMAs

Is Lupin Ltd. worth buying?

922 Votes:

Buy 72.78%

Sell 17.46%

Hold 9.76%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf